Hemogenyx Pharmaceuticals PLC

HEMO.UK

$0.02

Closing

▲0.47%

1D

▼-44.09%

YTD

HEMO

BBG00BDKH4C6

Market cap

$22.33M

52 week high

$0.09

52 week low

$0.02

Volume

915,686

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$22.33M

Analysts' Rating

-

Price Target (Mean)

Unable to collect data for some field(s).

Total Analysts

0

P/E

Operating Margin

0.00%

Beta

4.06

Revenue Growth (Annual)

-

52 week high

$0.09

52 week low

$0.02

Div. Yield

%

EPS Annual Growth

0.00

Company Profile

Hemogenyx Pharmaceuticals plc is a preclinical-stage biotechnology company. The Company is focused on the discovery, development and commercialization of treatments relating to bone marrow/hematopoietic (blood-forming) stem cell (BM/HSC) transplants for blood diseases, including leukemia, lymphoma and bone marrow failure and viral infections. It is developing several distinct and complementary product candidates, as well as a platform technology. To obviate the use of chemotherapeutic agents for conditioning of patients undergoing BM/HSC transplantations, the Company developed a method of selective elimination of hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in patients using highly specific CDX antibodies. It has developed postnatal human hemogenic endothelial cells (Hu-PHEC cells) to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers. It has developed HEMO-CAR-T, for the potential treatment of acute myeloid leukemia (AML).